Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Authors

  • Mary Abood Temple University https://orcid.org/0000-0002-1744-2820
  • Stephen P.H. Alexander University of Nottingham https://orcid.org/0000-0003-4417-497X
  • Francis Barth Sanofi Synthelabo Recherche
  • Tom I. Bonner National Institute of Mental Health
  • Heather Bradshaw Indiana University
  • Guy Cabral Medical College of Virginia
  • Pierre Casellas Université de Montpellier
  • Ben F. Cravatt Scripps Research Institute
  • William A. Devane Medical College of Virginia
  • Vincenzo Di Marzo CNR Institute of Biomolecular Chemistry https://orcid.org/0000-0002-1490-3070
  • Maurice R. Elphick Queen Mary University of London
  • Christian C. Felder Lilly Research Laboratories
  • Peter Greasley AstraZeneca R&D Mölndal
  • Miles Herkenham National Institute of Mental Health
  • Allyn C. Howlett North Carolina Central University
  • George Kunos National Institutes of Health
  • Ken Mackie University of Washington
  • Raphael Mechoulam Hebrew University
  • Roger G. Pertwee University of Aberdeen https://orcid.org/0000-0003-3227-2783
  • Ruth A. Ross University of Toronto

DOI:

https://doi.org/10.2218/gtopdb/F13/2019.4

Abstract

Cannabinoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Cannabinoid Receptors [107]) are activated by endogenous ligands that include N-arachidonoylethanolamine (anandamide), N-homo-γ-linolenoylethanolamine, N-docosatetra-7,10,13,16-enoylethanolamine and 2-arachidonoylglycerol. Potency determinations of endogenous agonists at these receptors are complicated by the possibility of differential susceptibility of endogenous ligands to enzymatic conversion [4].

There are currently three licenced cannabinoid medicines each of which contains a compound that can activate CB1 and CB2 receptors [104]. Two of these medicines were developed to suppress nausea and vomiting produced by chemotherapy. These are nabilone (Cesamet®), a synthetic CB1/CB2 receptor agonist, and synthetic Δ9-tetrahydrocannabinol (Marinol®; dronabinol), which can also be used as an appetite stimulant. The third medicine, Sativex®, contains mainly Δ9-tetrahydrocannabinol and cannabidiol, both extracted from cannabis, and is used to treat multiple sclerosis and cancer pain.

Downloads

Published

16-Sep-2019

Issue

Vol. 2019 No. 4 (2019)

Section

Summaries

How to Cite

“Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database” (2019) IUPHAR/BPS Guide to Pharmacology CITE, 2019(4). doi:10.2218/gtopdb/F13/2019.4.